Human 20S Proteasome Protein, CF

Catalog # Availability Size / Price Qty
E-360-050
Product Details
Citations (26)
FAQs
Reviews (1)

Human 20S Proteasome Protein, CF Summary

Product Specifications

Activity
The Human 20S Proteasome is able to degrade substrates in an ATP-independent manner. Reaction conditions will need to be optimized for each specific application. We recommend an initial Human 20S Proteasome concentration of 0.5-5 nM.
Source
Human erythrocyte-derived 20S Proteasome protein
The Human 20S Proteasome protein has been purified from human erythrocytes, which have been screened and are negative for hepatitis B surface antigen, antibodies to hepatitis C virus, HIV type 1 antigens, and antibodies to HIV type 1 and 2.
Predicted Molecular Mass
700 kDa

Product Datasheets

You must select a language.

x

E-360

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

E-360

Formulation Supplied as a 0.2 μm filtered solution in HEPES, NaCl and DTT.
Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -70 °C as supplied.
  • 3 months, -70 °C under sterile conditions after opening.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: 20S Proteasome

The 20S Proteasome is the catalytic core component of the multi-complex 26S Proteasome that selectively degrades intracellular proteins.  It is commonly associated with regulatory complexes, which include the 19S Proteasome, the PA28 alpha/beta complex, or the PA28 gamma complex (1). The 20S Proteasome is composed of 28 subunits arranged into four stacked rings (2,3). The outer rings, containing seven subunits each, are composed of closely-related but non-identical alpha subunits.  The amino-terminal tails of the alpha subunits form a gate that restricts substrate entry into the catalytic core.  The inner rings, also containing seven subunits each, are composed of closely-related but non-identical beta subunits.  The amino-terminal tails of six of the beta subunits, three per ring, have proteolytic activity. Inhibition of 20S Proteasome proteolytic core activity using small molecule inhibitors is a valuable tool for the functional study of a variety of proteins and for therapeutic intervention (4). The 20S Proteasome can be activated chemically by the addition of detergent or by the proteinaceous activator PA28 Activator alpha (5). 

The Human 20S Proteasome protein has been purified from human erythrocytes, which have been screened and are negative for hepatitis B surface antigen, antibodies to hepatitis C virus, HIV type 1 antigens, and antibodies to HIV type 1 and 2.

References
  1. Stadtmueller, B.M. & C.P. Hill (2011) Mol. Cell 41:8.
  2. Kim, H.M. et al. (2011) Biochim. Biophys. Acta 1809:67.
  3. Xie, Y. (2010) J. Mol. Cell Biol. 2:308.
  4. Kisselev, A.F. et al. (2012) Chem. Biol. 19:99.
  5. Ma, C.P. et al. (1992) J. Biol. Chem. 267:10515.
Alternate Names
20S Proteasome

Citations for Human 20S Proteasome Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

26 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. SARS-CoV-2 mutations affect antigen processing by the proteasome to alter CD8+ T cell responses
    Authors: Wellington, D;Yin, Z;Yu, Z;Heilig, R;Davis, S;Fischer, R;Felce, SL;Antoun, E;Hublitz, P;Beveridge, R;Dong, D;Liu, G;Yao, X;Peng, Y;Kessler, BM;Dong, T;
    Heliyon
    Species: N/A
    Sample Types: Peptide
    Applications: Bioassay
  2. Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug
    Authors: GR Tundo, D Sbardella, F Oddone, G Grasso, S Marini, MG Atzori, AM Santoro, D Milardi, F Bellia, G Macari, G Graziani, F Polticelli, P Cascio, M Parravano, M Coletta
    Biomolecules, 2022-02-16;12(2):.
    Species: Human
    Sample Types: Protein
    Applications: Bioassay
  3. Inhibition of mitochondrial LonP1 protease by allosteric blockade of ATP -binding and -hydrolysis via CDDO and its derivatives
    Authors: J Lee, AK Pandey, S Venkatesh, J Thilagavat, T Honda, K Singh, CK Suzuki
    The Journal of Biological Chemistry, 2022-02-11;0(0):101719.
  4. Hepatitis C virus induces oxidation and degradation of apolipoprotein B to enhance lipid accumulation and promote viral production
    Authors: B Wang, Y Zhu, C Yu, C Zhang, Q Tang, H Huang, Z Zhao
    PloS Pathogens, 2021-09-07;17(9):e1009889.
    Species: Human
    Sample Types: Protein
    Applications: Bioassay
  5. Cryo-EM structures of the human PA200 and PA200-20S complex reveal regulation of proteasome gate opening and two PA200 apertures
    Authors: H Guan, Y Wang, T Yu, Y Huang, M Li, AFUH Saeed, V Per?ulija, D Li, J Xiao, D Wang, P Zhu, S Ouyang
    PLoS Biol., 2020-03-05;18(3):e3000654.
    Species: Human
    Sample Types: Whoel Cells
    Applications: Bioassay
  6. A dual inhibitor of the proteasome catalytic subunits LMP2 and Y attenuates disease progression in mouse models of Alzheimer's disease
    Authors: IJ Yeo, MJ Lee, A Baek, Z Miller, D Bhattarai, YM Baek, HJ Jeong, YK Kim, DE Kim, JT Hong, KB Kim
    Sci Rep, 2019-12-05;9(1):18393.
    Species: Mouse
    Sample Types: Tissue Culture Supernates
    Applications: Bioassay
  7. Discovery of Immunoproteasome Inhibitors Using Large-Scale Covalent Virtual Screening
    Authors: A Scarpino, D Bajusz, M Proj, M Gobec, I Sosi?, S Gobec, GG Ferenczy, GM Keser?
    Molecules, 2019-07-16;24(14):.
    Species: Human
    Sample Types: Small Molecule
    Applications: Bioassay
  8. A new gold(I) complex-Au(PPh3)PT is a deubiquitinase inhibitor and inhibits tumor growth
    Authors: X Li, Q Huang, H Long, P Zhang, H Su, J Liu
    EBioMedicine, 2018-12-05;0(0):.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Bioassay
  9. REG? controls Hippo signaling and reciprocal NF-?B-YAP regulation to promote colon cancer
    Authors: X Li, Q Wang, X Gao, T Yu, L Yuan, J Dai, W Wang, G Chen, C Jiao, W Zhou, Q Huang, L Cui, P Zhang, RE Moses, J Yang, F Chen, J Fu, J Xiao, L Li, Y Dang
    Clin. Cancer Res., 2018-02-06;0(0):.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Bioassay
  10. Piperlongumine and some of its analogs inhibit selectively the human immunoproteasome over the constitutive proteasome
    Authors: E Bosc, J Nastri, V Lefort, M Valli, F Contiguiba, R Pioli, M Furlan, VDS Bolzani, C El Amri, M Reboud-Rav
    Biochem. Biophys. Res. Commun., 2018-02-02;496(3):961-966.
    Species: Human
    Sample Types: Small Molecule
    Applications: Bioassay
  11. Immunoproteasome functions explained by divergence in cleavage specificity and regulation
    Authors: MB Winter, F La Greca, S Arastu-Kap, F Caiazza, P Cimermanci, TJ Buchholz, JL Anderl, M Ravalin, MF Bohn, A Sali, AJ O'Donoghue, CS Craik
    Elife, 2017-11-28;6(0):.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Bioassay
  12. Immunohistochemical analysis reveals variations in proteasome tissue expression in C. elegans
    Authors: E Mikkonen, C Haglund, CI Holmberg
    PLoS ONE, 2017-08-17;12(8):e0183403.
    Species: C. elegans
    Sample Types: Whole Tissue
    Applications: IHC-P
  13. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens
    Authors: AY Chang, T Dao, RS Gejman, CA Jarvis, A Scott, L Dubrovsky, MD Mathias, T Korontsvit, V Zakhaleva, M Curcio, RC Hendrickso, C Liu, DA Scheinberg
    J. Clin. Invest., 2017-06-19;127(7):2705-2718.
    Applications: Enzyme Assay
  14. Diabetogenic agent alloxan is a proteasome inhibitor
    Authors: W Zhou, L Wei, T Xiao, C Lai, M Peng, L Xu, X Luo, S Deng, F Zhang
    Biochem. Biophys. Res. Commun., 2017-05-11;0(0):.
    Applications: Bioassay
  15. APEH Inhibition Affects Osteosarcoma Cell Viability via Downregulation of the Proteasome
    Int J Mol Sci, 2016-09-23;17(10):.
    Species: Human
    Sample Types: Protein
    Applications: Bioassay
  16. Copper(II) ions affect the gating dynamics of the 20S proteasome: a molecular and in cell study
    Sci Rep, 2016-09-16;6(0):33444.
    Applications: Bioassay
  17. Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay
    Authors: SJ Lee, K Levitsky, F Parlati, MK Bennett, S Arastu-Kap, L Kellerman, TF Woo, AF Wong, KP Papadopoul, R Niesvizky, AZ Badros, R Vij, S Jagannath, D Siegel, M Wang, GJ Ahmann, CJ Kirk
    Br J Haematol, 2016-04-12;0(0):.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Bioassay
  18. Structure- and function-based design of Plasmodium-selective proteasome inhibitors.
    Authors: Li H, O'Donoghue A, van der Linden W, Xie S, Yoo E, Foe I, Tilley L, Craik C, da Fonseca P, Bogyo M
    Nature, 2016-02-11;530(7589):233-6.
    Species: Human
    Sample Types: Protein
    Applications: Enzyme Assay
  19. VR23: A Quinoline-Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification.
    Authors: Pundir S, Vu H, Solomon V, McClure R, Lee H
    Cancer Res, 2015-08-03;75(19):4164-75.
  20. Cleavage Specificity of Mycobacterium tuberculosis ClpP1P2 Protease and Identification of Novel Peptide Substrates and Boronate Inhibitors with Anti-bacterial Activity.
    Authors: Akopian T, Kandror O, Tsu C, Lai J, Wu W, Liu Y, Zhao P, Park A, Wolf L, Dick L, Rubin E, Bachovchin W, Goldberg A
    J Biol Chem, 2015-03-10;290(17):11008-20.
    Species: Bacteria - Mycobacterium tuberculosis
    Sample Types: Protein
    Applications: Bioassay
  21. Nucleolar stress induces ubiquitination-independent proteasomal degradation of PICT1 protein.
    Authors: Maehama, Tomohiko, Kawahara, Kohichi, Nishio, Miki, Suzuki, Akira, Hanada, Kentaro
    J Biol Chem, 2014-07-25;289(30):20802-12.
    Species: Human
    Sample Types: Protein
    Applications: Bioassay
  22. Inhibition of human and yeast 20S proteasome by analogues of trypsin inhibitor SFTI-1.
    Authors: Debowski D, Pikula M, Lubos M, Langa P, Trzonkowski P, Lesner A, Legowska A, Rolka K
    PLoS ONE, 2014-02-25;9(2):e89465.
    Applications: Bioassay
  23. Gold(III)-dithiocarbamato peptidomimetics in the forefront of the targeted anticancer therapy: preclinical studies against human breast neoplasia.
    Authors: Nardon, Chiara, Schmitt, Sara M, Yang, Huanjie, Zuo, Jian, Fregona, Dolores, Dou, Q Ping
    PLoS ONE, 2014-01-02;9(1):e84248.
    Species: Human
    Sample Types: Cell Extracts
  24. RedOx status, proteasome and APEH: insights into anticancer mechanisms of t10,c12-conjugated linoleic acid isomer on A375 melanoma cells.
    Authors: Bergamo P, Cocca E, Palumbo R, Gogliettino M, Rossi M, Palmieri G
    PLoS ONE, 2013-11-19;8(11):e80900.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Bioassay
  25. Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells.
    Authors: Henle A, Erskine C, Benson L, Clynes R, Knutson K
    J Immunol, 2012-11-23;190(1):479-88.
    Applications: Bioassay
  26. Selective cytotoxicity of amidinopiperidine based compounds towards Burkitt's lymphoma cells involves proteasome inhibition.
    Authors: Gobec M, Obreza A, Prijatelj M, Brus B, Gobec S, Mlinaric-Rascan I
    PLoS ONE, 2012-07-30;7(7):e41961.
    Species: Human
    Sample Types: Protein
    Applications: Bioassay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Human 20S Proteasome Protein, CF

Average Rating: 5 (Based on 1 Review)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human 20S Proteasome Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human 20S Proteasome Protein, CF
By Anonymous on 09/29/2021
Application: Enzymatic activity in vitro
Reason for Rating: Works excellent for the in vitro p100 cleavage assay.